Comprehensive Mapping of HIV-1 Escape from a Broadly Neutralizing Antibody

Cell Host and Microbe

Volumn 21, Issue 6, 2017, Pages 777-787.e4

  Dingens, Adam S ^a,b   Haddox, Hugh K ^a,b   Overbaugh, Julie ^a   Bloom, Jesse D ^a  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

antibody escape; broadly neutralizing antibody; deep mutational scanning; epitope; HIV 1; mutational antigenic profiling; PGT151

Indexed keywords

ALANINE; AMINO ACID; EPITOPE; GLYCAN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN; GLYCOPROTEIN GP 120; POLYSACCHARIDE;

ARTICLE; CONTROLLED STUDY; ESCAPE BEHAVIOR; HIGH THROUGHPUT SEQUENCING; HUMAN IMMUNODEFICIENCY VIRUS 1; MUTANT; MUTATION; NONHUMAN; PRIORITY JOURNAL; VIRUS REPLICATION; AMINO ACID SEQUENCE; ANIMAL; CELL LINE; EPITOPE MAPPING; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE EVASION; IMMUNOLOGY; MOUSE; SERODIAGNOSIS; VIROLOGY;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, NEUTRALIZING; CELL LINE; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; EPITOPE MAPPING; EPITOPES; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; IMMUNE EVASION; MICE; MUTATION; NEUTRALIZATION TESTS; POLYSACCHARIDES;

EID: 85020234897     PISSN: 19313128     EISSN: 19346069     Source Type: Journal    
DOI: 10.1016/j.chom.2017.05.003     Document Type: Article

References (62)

1. Baker, N.A., Sept, D., Joseph, S., Holst, M.J., McCammon, J.A., Electrostatics of nanosystems: application to microtubules and the ribosome. Proc. Natl. Acad. Sci. USA 98 (2001), 10037–10041.
2. Bar, K.J., Sneller, M.C., Harrison, L.J., Justement, J.S., Overton, E.T., Petrone, M.E., Salantes, D.B., Seamon, C.A., Scheinfeld, B., Kwan, R.W., et al. Effect of HIV antibody VRC01 on viral rebound after treatment interruption. N. Engl. J. Med. 375 (2016), 2037–2050.
3. Barouch, D.H., Whitney, J.B., Moldt, B., Klein, F., Oliveira, T.Y., Liu, J., Stephenson, K.E., Chang, H.-W., Shekhar, K., Gupta, S., et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503 (2013), 224–228.
4. Benki, S., McClelland, R.S., Emery, S., Baeten, J.M., Richardson, B.A., Lavreys, L., Mandaliya, K., Overbaugh, J., Quantification of genital human immunodeficiency virus type 1 (HIV-1) DNA in specimens from women with low plasma HIV-1 RNA levels typical of HIV-1 nontransmitters. J. Clin. Microbiol. 44 (2006), 4357–4362.
5. Blattner, C., Lee, J.H., Sliepen, K., Derking, R., Falkowska, E., de la Peña, A.T., Cupo, A., Julien, J.-P., van Gils, M., Lee, P.S., et al. Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. Immunity 40 (2014), 669–680.
6. Bloom, J.D., An experimentally determined evolutionary model dramatically improves phylogenetic fit. Mol. Biol. Evol. 31 (2014), 1956–1978.
7. Bloom, J.D., Software for the analysis and visualization of deep mutational scanning data. BMC Bioinformatics, 16, 2015, 168.
8. Boyd, D.F., Peterson, D., Haggarty, B.S., Jordan, A.P.O., Hogan, M.J., Goo, L., Hoxie, J.A., Overbaugh, J., Mutations in HIV-1 envelope that enhance entry with the macaque CD4 receptor alter antibody recognition by disrupting quaternary interactions within the trimer. J. Virol. 89 (2015), 894–907.
9. Caskey, M., Klein, F., Lorenzi, J.C.C., Seaman, M.S., West, A.P. Jr., Buckley, N., Kremer, G., Nogueira, L., Braunschweig, M., Scheid, J.F., et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 522 (2015), 487–491.
10. Caskey, M., Schoofs, T., Gruell, H., Settler, A., Karagounis, T., Kreider, E.F., Murrell, B., Pfeifer, N., Nogueira, L., Oliveira, T.Y., et al. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. Nat. Med. 23 (2017), 185–191.
11. Chakrabarti, L., Emerman, M., Tiollais, P., Sonigo, P., The cytoplasmic domain of simian immunodeficiency virus transmembrane protein modulates infectivity. J. Virol. 63 (1989), 4395–4403.
12. Clackson, T., Wells, J.A., A hot spot of binding energy in a hormone-receptor interface. Science 267 (1995), 383–386.
13. Cortez, V., Wang, B., Dingens, A., Chen, M.M., Ronen, K., Georgiev, I.S., McClelland, R.S., Overbaugh, J., The broad neutralizing antibody responses after HIV-1 superinfection are not dominated by antibodies directed to epitopes common in single infection. PLoS Pathog., 11, 2015, e1004973.
14. Crooks, G.E., Hon, G., Chandonia, J.-M., Brenner, S.E., WebLogo: a sequence logo generator. Genome Res. 14 (2004), 1188–1190.
15. Cunningham, B.C., Wells, J.A., Comparison of a structural and a functional epitope. J. Mol. Biol. 234 (1993), 554–563.
16. Diskin, R., Scheid, J.F., Marcovecchio, P.M., West, A.P. Jr., Klein, F., Gao, H., Gnanapragasam, P.N.P., Abadir, A., Seaman, M.S., Nussenzweig, M.C., Bjorkman, P.J., Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science 334 (2011), 1289–1293.
17. Diskin, R., Klein, F., Horwitz, J.A., Halper-Stromberg, A., Sather, D.N., Marcovecchio, P.M., Lee, T., West, A.P. Jr., Gao, H., Seaman, M.S., et al. Restricting HIV-1 pathways for escape using rationally designed anti-HIV-1 antibodies. J. Exp. Med. 210 (2013), 1235–1249.
18. Doud, M.B., Bloom, J.D., Accurate measurement of the effects of all amino-acid mutations on influenza hemagglutinin. Viruses, 8, 2016, 155.
19. Doud, M.B., Hensley, S.E., Bloom, J.D., Complete mapping of viral escape from neutralizing antibodies. PLoS Pathog., 13, 2017, e1006271.
20. Falkowska, E., Ramos, A., Feng, Y., Zhou, T., Moquin, S., Walker, L.M., Wu, X., Seaman, M.S., Wrin, T., Kwong, P.D., et al. PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4. J. Virol. 86 (2012), 4394–4403.
21. Falkowska, E., Le, K.M., Ramos, A., Doores, K.J., Lee, J.H., Blattner, C., Ramirez, A., Derking, R., van Gils, M.J., Liang, C.-H., et al. Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. Immunity 40 (2014), 657–668.
22. Goo, L., Milligan, C., Simonich, C.A., Nduati, R., Overbaugh, J., Neutralizing antibody escape during HIV-1 mother-to-child transmission involves conformational masking of distal epitopes in envelope. J. Virol. 86 (2012), 9566–9582.
23. Haddox, H.K., Dingens, A.S., Bloom, J.D., Experimental estimation of the effects of all amino-acid mutations to HIV's envelope protein on viral replication in cell culture. PLoS Pathog., 12, 2016, e1006114.
24. Hessell, A.J., Poignard, P., Hunter, M., Hangartner, L., Tehrani, D.M., Bleeker, W.K., Parren, P.W.H.I., Marx, P.A., Burton, D.R., Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. 15 (2009), 951–954.
25. Horwitz, J.A., Halper-Stromberg, A., Mouquet, H., Gitlin, A.D., Tretiakova, A., Eisenreich, T.R., Malbec, M., Gravemann, S., Billerbeck, E., Dorner, M., et al. HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc. Natl. Acad. Sci. USA 110 (2013), 16538–16543.
26. Jabara, C.B., Jones, C.D., Roach, J., Anderson, J.A., Swanstrom, R., Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID. Proc. Natl. Acad. Sci. USA 108 (2011), 20166–20171.
27. Jardine, J.G., Kulp, D.W., Havenar-Daughton, C., Sarkar, A., Briney, B., Sok, D., Sesterhenn, F., Ereño-Orbea, J., Kalyuzhniy, O., Deresa, I., et al. HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen. Science 351 (2016), 1458–1463.
28. Klein, F., Halper-Stromberg, A., Horwitz, J.A., Gruell, H., Scheid, J.F., Bournazos, S., Mouquet, H., Spatz, L.A., Diskin, R., Abadir, A., et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 492 (2012), 118–122.
29. Kong, R., Xu, K., Zhou, T., Acharya, P., Lemmin, T., Liu, K., Ozorowski, G., Soto, C., Taft, J.D., Bailer, R.T., et al. Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody. Science 352 (2016), 828–833.
30. Korber, B.T., Foley, B.T., Kuiken, C.L., Pillai, S.K., Sodroski, J.G., Numbering positions in HIV relative to HXB2CG. Hum. Retroviruses AIDS 3 (1998), 102–111.
31. Lee, J.H., Ozorowski, G., Ward, A.B., Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimer. Science 351 (2016), 1043–1048.
32. Lehman, D.A., Baeten, J.M., McCoy, C.O., Weis, J.F., Peterson, D., Mbara, G., Donnell, D., Thomas, K.K., Hendrix, C.W., Marzinke, M.A., et al., Partners PrEP Study Team. Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis. J. Infect. Dis. 211 (2015), 1211–1218.
33. Li, Y., Luo, L., Thomas, D.Y., Kang, C.Y., Control of expression, glycosylation, and secretion of HIV-1 gp120 by homologous and heterologous signal sequences. Virology 204 (1994), 266–278.
34. Li, Y., O'Dell, S., Walker, L.M., Wu, X., Guenaga, J., Feng, Y., Schmidt, S.D., McKee, K., Louder, M.K., Ledgerwood, J.E., et al. Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. J. Virol. 85 (2011), 8954–8967.
35. Lynch, R.M., Boritz, E., Coates, E.E., DeZure, A., Madden, P., Costner, P., Enama, M.E., Plummer, S., Holman, L., Hendel, C.S., et al., VRC 601 Study Team. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci. Transl. Med., 7, 2015, 319ra206.
36. Lynch, R.M., Wong, P., Tran, L., O'Dell, S., Nason, M.C., Li, Y., Wu, X., Mascola, J.R., HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies. J. Virol. 89 (2015), 4201–4213.
37. Margolis, D.M., Koup, R.A., Ferrari, G., HIV antibodies for treatment of HIV infection. Immunol. Rev. 275 (2017), 313–323.
38. Mascola, J.R., Lewis, M.G., Stiegler, G., Harris, D., VanCott, T.C., Hayes, D., Louder, M.K., Brown, C.R., Sapan, C.V., Frankel, S.S., et al. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73 (1999), 4009–4018.
39. Mascola, J.R., Stiegler, G., VanCott, T.C., Katinger, H., Carpenter, C.B., Hanson, C.E., Beary, H., Hayes, D., Frankel, S.S., Birx, D.L., Lewis, M.G., Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6 (2000), 207–210.
40. McCoy, L.E., Falkowska, E., Doores, K.J., Le, K., Sok, D., van Gils, M.J., Euler, Z., Burger, J.A., Seaman, M.S., Sanders, R.W., et al. Incomplete neutralization and deviation from sigmoidal neutralization curves for HIV broadly neutralizing monoclonal antibodies. PLoS Pathog., 11, 2015, e1005110.
41. Moldt, B., Rakasz, E.G., Schultz, N., Chan-Hui, P.-Y., Swiderek, K., Weisgrau, K.L., Piaskowski, S.M., Bergman, Z., Watkins, D.I., Poignard, P., Burton, D.R., Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc. Natl. Acad. Sci. USA 109 (2012), 18921–18925.
42. Parren, P.W.H.I., Marx, P.A., Hessell, A.J., Luckay, A., Harouse, J., Cheng-Mayer, C., Moore, J.P., Burton, D.R., Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75 (2001), 8340–8347.
43. Pegu, A., Yang, Z.Y., Boyington, J.C., Wu, L., Ko, S.-Y., Schmidt, S.D., McKee, K., Kong, W.-P., Shi, W., Chen, X., et al. Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Sci. Transl. Med., 6, 2014, 243ra88.
44. Pegu, A., Hessell, A.J., Mascola, J.R., Haigwood, N.L., Use of broadly neutralizing antibodies for HIV-1 prevention. Immunol. Rev. 275 (2017), 296–312.
45. Poignard, P., Sabbe, R., Picchio, G.R., Wang, M., Gulizia, R.J., Katinger, H., Parren, P.W.H.I., Mosier, D.E., Burton, D.R., Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity 10 (1999), 431–438.
46. Poss, M., Overbaugh, J., Variants from the diverse virus population identified at seroconversion of a clade A human immunodeficiency virus type 1-infected woman have distinct biological properties. J. Virol. 73 (1999), 5255–5264.
47. Provine, N.M., Puryear, W.B., Wu, X., Overbaugh, J., Haigwood, N.L., The infectious molecular clone and pseudotyped virus models of human immunodeficiency virus type 1 exhibit significant differences in virion composition with only moderate differences in infectivity and inhibition sensitivity. J. Virol. 83 (2009), 9002–9007.
48. Scheid, J.F., Horwitz, J.A., Bar-On, Y., Kreider, E.F., Lu, C.-L., Lorenzi, J.C.C., Feldmann, A., Braunschweig, M., Nogueira, L., Oliveira, T., et al. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature 535 (2016), 556–560.
49. Shingai, M., Nishimura, Y., Klein, F., Mouquet, H., Donau, O.K., Plishka, R., Buckler-White, A., Seaman, M., Piatak, M. Jr., Lifson, J.D., et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 503 (2013), 277–280.
50. Simonich, C.A., Williams, K.L., Verkerke, H.P., Williams, J.A., Nduati, R., Lee, K.K., Overbaugh, J., HIV-1 neutralizing antibodies with limited hypermutation from an infant. Cell 166 (2016), 77–87.
51. Steichen, J.M., Kulp, D.W., Tokatlian, T., Escolano, A., Dosenovic, P., Stanfield, R.L., McCoy, L.E., Ozorowski, G., Hu, X., Kalyuzhniy, O., et al. HIV vaccine design to target germline precursors of glycan-dependent broadly neutralizing antibodies. Immunity 45 (2016), 483–496.
52. Strain, M.C., Lada, S.M., Luong, T., Rought, S.E., Gianella, S., Terry, V.H., Spina, C.A., Woelk, C.H., Richman, D.D., Highly precise measurement of HIV DNA by droplet digital PCR. PLoS One, 8, 2013, e55943.
53. Todd, C.A., Greene, K.M., Yu, X., Ozaki, D.A., Gao, H., Huang, Y., Wang, M., Li, G., Brown, R., Wood, B., et al. Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells. J. Immunol. Methods 375 (2012), 57–67.
54. Trkola, A., Kuster, H., Rusert, P., Joos, B., Fischer, M., Leemann, C., Manrique, A., Huber, M., Rehr, M., Oxenius, A., et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat. Med. 11 (2005), 615–622.
55. Tural, C., Ruiz, L., Holtzer, C., Schapiro, J., Viciana, P., González, J., Domingo, P., Boucher, C., Rey-Joly, C., Clotet, B., Havana Study Group. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 16 (2002), 209–218.
56. van Gils, M.J., van den Kerkhof, T.L.G.M., Ozorowski, G., Cottrell, C.A., Sok, D., Pauthner, M., Pallesen, J., de Val, N., Yasmeen, A., de Taeye, S.W., et al. An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability. Nat. Microbiol., 2, 2016, 16199.
57. Vercauteren, J., Vandamme, A.M., Algorithms for the interpretation of HIV-1 genotypic drug resistance information. Antiviral Res. 71 (2006), 335–342.
58. Wibmer, C.K., Gorman, J., Ozorowski, G., Bhiman, J.N., Sheward, D.J., Elliott, D.H., Rouelle, J., Smira, A., Joyce, M.G., Ndabambi, N., et al. Structure and recognition of a novel HIV-1 gp120-gp41 interface antibody that caused MPER exposure through viral escape. PLoS Pathog., 13, 2017, e1006074.
59. Wu, X., Kong, X.-P., Antigenic landscape of the HIV-1 envelope and new immunological concepts defined by HIV-1 broadly neutralizing antibodies. Curr. Opin. Immunol. 42 (2016), 56–64.
60. Wu, X., Parast, A.B., Richardson, B.A., Nduati, R., John-Stewart, G., Mbori-Ngacha, D., Rainwater, S.M.J., Overbaugh, J., Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant. J. Virol. 80 (2006), 835–844.
61. Wu, N.C., Du, Y., Le, S., Young, A.P., Zhang, T.-H., Wang, Y., Zhou, J., Yoshizawa, J.M., Dong, L., Li, X., et al. Coupling high-throughput genetics with phylogenetic information reveals an epistatic interaction on the influenza A virus M segment. BMC Genomics, 17, 2016, 46.
62. Yuste, E., Reeves, J.D., Doms, R.W., Desrosiers, R.C., Modulation of Env content in virions of simian immunodeficiency virus: correlation with cell surface expression and virion infectivity. J. Virol. 78 (2004), 6775–6785.